EW Weekly, November 20, 2020

- Two BAK-preserved eye drops inactivate SARS-CoV-2
- Promising results from supraciliary MIGS device
- New data from Phase 2 clinical trial for dry eye nasal spray
- Real-world data from cataract surgery intraocular anti-inflammatory injection
- ASCRS launches Journal Club
- 20/Happy in 2020: ASCRS continues master class
- Research highlights
- Product news
- A recent paper published in the journal Eye discussed “mask-associated dry eye” (MADE) and a specific case of postoperative MADE. Overall, the authors described MADE as a form of dry eye that occurs due to ill-fitting masks that leak air. They reported a patient who had uncomplicated cataract surgery. Initially postop the patient was pleased with her vision, but the authors noted that hours later she experienced blurred vision and discomfort. They observed UCVA of counting fingers, corneal haze, and superficial staining. There was no epithelial defect, wound leak, IOP was normal, and there was no intraocular inflammation. The patient was advised to continue postop drops per recommendations and not use her face mask as much as possible. The patient’s vision was restored within 2 days and no dry eye was noted at postop week 1. The authors think this is the first published reported case of visual loss due to MADE after cataract surgery. They think the patient’s mask, which was loose at the nose, directed breath onto the still anesthetized ocular surface, creating a type of exposure keratopathy. They recommended taping the top of the face mask pre- and postop to restrict air that could be directed up toward the eye postop.
- Risk of developing high myopia in adulthood based on age of myopia onset was evaluated using Chinese dataset with 12 years of follow-up. The research is based on an ongoing, population-based prospective cohort twin study that began in 2006. The twins were followed up until 17 years or older, and 443 who developed myopia were included in this study. The mean age of myopia onset in the group was 11.7 years old and 12.2% of the group developed what was considered high myopia (–6 D or greater) by adulthood. The researchers found that the younger the age of myopia onset, the greater chance of developing high myopia. They reported that each year of delayed onset of myopia reduced the likelihood of developing high myopia, emphasizing the importance of myopia prevention. The research is published in JAMA Ophthalmology.
-
The European Medicines Agency Committee for Medicinal Products for Human Use recommended approval for the marketing authorization application of Aerie Pharmaceutical’s Roclanda (netarsudil and latanoprost ophthalmic solution, 0.02%/0.005%). This recommendation goes to the European Commission for a final decision, which is expected within 2 months. Roclanda is already FDA approved and marketed as Rocklatan in the U.S.
- Lumenis launched Digital Duet, described by the company as the first digital SLT-YAG system on the market.
- Topcon launched Chronos Automated Binocular Refraction System with SightPilot guided refraction software.
- EyeMD EMR Healthcare Systems unveiled its EyeMD EMR 2.0, an all-in-one EMR, PM, and PACS system.
- Alcon launched the AcrySof IQ Vivity presbyopia-correcting IOL in Canada.
This issue of EyeWorld Weekly was edited by Stacy Jablonski and Vanessa Caceres.
EyeWorld Weekly (ISSN 1089-0319), a digital publication of the American Society of Cataract and Refractive Surgery (ASCRS), is published every Friday, distributed by email, and posted live on Friday.
Medical Editors: Eric Donnenfeld, MD, Chief Medical Editor; Rosa Braga-Mele, MD, Cataract Editor; Clara Chan, MD, Cornea Editor; Nathan Radcliffe, MD, Glaucoma Editor; and Vance Thompson, MD, Refractive Editor
For sponsorship opportunities or membership information, contact: ASCRS • 4000 Legato Rd. • Suite 700 • Fairfax, VA 22033 • Phone: 703-591-2220 • Fax: 703-591-0614 • Email: ASCRS Opinions expressed in EyeWorld Weekly do not necessarily reflect those of ASCRS. Mention of products or services does not constitute an endorsement by ASCRS.
Click here to view our Legal Notice.
Copyright 2021, EyeWorld News Service, a division of ASCRSMedia. All rights reserved.